Supplementary Material for: Bone Turnover, Mineralization, and Volume Estimated by ¹⁸F-Sodium Fluoride PET/CT and Biomarkers in Chronic Kidney Disease: Mineral and Bone Disorder Compared with Bone Biopsy

<b><i>Introduction:</i></b> Invasive bone biopsy to assess bone metabolism in patients with chronic kidney disease-mineral and bone disorder may be replaced by the noninvasive ¹⁸F-NaF PET/CT and biomarkers of bone metabolism. We aimed to compare parameters of bone turnover, mineralization, and volume assessed by bone biopsies with results derived from ¹⁸F-NaF PET/CT and biomarkers (bone-specific alkaline phosphatase, osteocalcin, fibroblast growth factor 23, and osteoprotegerin). <b><i>Methods:</i></b> A cross-sectional study included 17 dialysis patients, and results from ¹⁸F-NaF PET/CT scans and the biomarkers were directly compared with the results of histomorphometric analyses of tetracycline double-labeled trans-iliac bone biopsies. <b><i>Results:</i></b> Bone biopsies showed 40% high, 20% normal, and 40% low bone turnover. No biopsies had generalized abnormal mineralization, and the bone volume/total tissue volume was low in 80% and high in 7%. The pelvic skeletal plasma clearance (K_i) from ¹⁸F-NaF PET/CT correlated with bone turnover parameters obtained by bone biopsy (activation frequency: <i>r</i> = 0.82, <i>p</i> &lt; 0.01; bone formation rate/bone surface: <i>r</i> = 0.81, <i>p</i> &lt; 0.01), and K_i defined low turnover with high sensitivity (83%) and specificity (100%). CT-derived radiodensity correlated with bone volume, <i>r</i> = 0.82, <i>p</i> &lt; 0.01. Of the biomarkers, only osteocalcin showed a correlation with turnover assessed by histomorphometry. <b><i>Conclusion:</i></b> In conclusion, ¹⁸F-NaF PET/CT may be applicable for noninvasive assessment of bone turnover and volume in CKD-MBD.

<b><i>引言：</i></b> 针对慢性肾脏病-矿物质和骨异常（chronic kidney disease-mineral and bone disorder, CKD-MBD）患者，评估骨代谢的侵入性骨活检可被无创的氟[¹⁸F]化钠PET/CT（¹⁸F-NaF PET/CT）与骨代谢标志物替代。本研究旨在对比骨活检所评估的骨转换、矿化及容积参数，与氟[¹⁸F]化钠PET/CT及骨代谢标志物（骨特异性碱性磷酸酶（bone-specific alkaline phosphatase）、骨钙素（osteocalcin）、成纤维细胞生长因子23（fibroblast growth factor 23）及骨保护素（osteoprotegerin））所得的结果。<b><i>方法：</i></b> 本横断面研究纳入17名透析患者，将氟[¹⁸F]化钠PET/CT扫描结果与骨代谢标志物检测结果，直接与四环素双标记经髂骨骨活检的组织形态计量学分析结果进行对比。<b><i>结果：</i></b> 骨活检结果显示，40%的患者存在高骨转换，20%为正常骨转换，40%为低骨转换。无活检标本出现广泛性矿化异常；骨容积/总组织容积方面，80%的患者偏低，7%偏高。氟[¹⁸F]化钠PET/CT所得的骨盆骨骼血浆清除率（K_i）与骨活检获取的骨转换参数具有相关性（激活频率：*r*=0.82，*p*<0.01；骨形成率/骨表面积：*r*=0.81，*p*<0.01），且K_i诊断低骨转换的灵敏度达83%、特异度达100%。CT衍生放射密度与骨容积具有相关性（*r*=0.82，*p*<0.01）。在所有骨代谢标志物中，仅骨钙素与组织形态计量学评估的骨转换具有相关性。<b><i>结论：</i></b> 综上，氟[¹⁸F]化钠PET/CT可用于慢性肾脏病-矿物质和骨异常患者骨转换与骨容积的无创评估。

搜集汇总

背景与挑战

背景概述

该数据集是2022年发布的医学研究补充材料，旨在比较非侵入性18F-NaF PET/CT和生物标志物与侵入性骨活检在评估慢性肾脏病-矿物质和骨代谢紊乱患者骨代谢方面的效果。研究基于17名透析患者的横断面数据，发现PET/CT参数与骨活检结果显著相关，表明其可能替代骨活检进行非侵入性评估。数据集包含两个文档文件，聚焦于骨转换、矿化和体积的测量方法对比。